Search Results

BioMark Diagnostics Inc, an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic partnership

RUBIX LS, a minority-led life science research firm focusing on solutions to support minorities within clinical trials, announced that it has formally launched its therapeutics division.

Culturally-Centric Life Science Company aggressively accelerates the development of the lead platform StarSense and expand the development of a Rubix LS owned clinical trial site for launching clinical trials.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC) in EU country Latvia.

Rubix Life Sciences has launched a dedicated therapeutics division to focus on infectious and neurodegenerative diseases.

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV.

Biotech firm Rubix LS announces critical milestone achievement for their lead combination device that halted the progression of osteonecrotic disease in 98% of participants.

Lichen striatus (LS), a skin condition manifesting as linear eruptions following Blaschko’s lines on the trunk or limbs of children, is often accompanied by hypopigmentation (loss of melanin or skin color).

Nouscom today announced that promising interim data from a Phase 1b trial evaluating NOUS-209 in Lynch Syndrome (LS) carriers was published in a Late-breaking Abstract and will be presented in an oral abstract presentation on 4th November 2023 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, USA.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has entered into an agreement with LS Associates, a division of LifeSci Advisors, LLC, pursuant to which LSA will provide certain consulting services to the Company, including but not limited to, arranging for the provision of the Company’s Interim Chief Financial Officer.